Gilead Sciences (NASDAQ:GILD – Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03, Zacks reports. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter last year, the business earned $1.90 earnings per share. Gilead Sciences updated its FY 2026 guidance to 8.450-8.850 EPS.
Here are the key takeaways from Gilead Sciences’ conference call:
- Gilead closed 2025 with strong results — full‑year product sales of $28.9B (base business $28B), HIV sales of $20.8B (+6% y/y; +10% excluding a ~$900M Part D headwind) — and guided 2026 total product sales of $29.6–$30.0B with non‑GAAP EPS of $8.45–$8.85, noting no major product LOEs until 2036.
- Management highlighted a catalyst‑rich 2026 with up to four planned commercial launches — including Trodelvy (1L metastatic TNBC), a daily oral combo Biclen (bictegravir+lenacapavir), Anito‑cel (BCMA CAR‑T) and bulevirtide — plus multiple phase III readouts and expected FDA decisions that could materially expand revenue.
- Near‑term headwinds include the December drug‑pricing agreement and proposed ACA changes that together create an estimated ~2% drag on 2026 growth, the 2025 ~$1.1B Part D redesign impact, a large expected decline in Veklury revenue, and continued competitive pressure on Kite cell‑therapy revenues (Kite revenue expected to fall ~10% in 2026).
- The twice‑yearly PrEP injectable Yes2Go (Sunlenca) is rapidly scaling — ~90% payer coverage (≈90% with $0 copay), $150M revenue in 2025, and management targets ≈$800M in 2026 — positioning it as a potential long‑term growth driver, though long‑term refill/persistency remains early and is being monitored.
Gilead Sciences Trading Down 2.9%
Shares of Gilead Sciences stock traded down $4.45 during trading on Tuesday, reaching $147.23. 10,737,165 shares of the company were exchanged, compared to its average volume of 7,852,057. Gilead Sciences has a twelve month low of $93.37 and a twelve month high of $153.13. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $182.67 billion, a price-to-earnings ratio of 22.83, a P/E/G ratio of 0.80 and a beta of 0.36. The business has a 50-day moving average price of $127.92 and a 200-day moving average price of $121.31.
Wall Street Analyst Weigh In
Read Our Latest Report on Gilead Sciences
Insider Buying and Selling
In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the sale, the insider directly owned 107,193 shares in the company, valued at approximately $13,491,310.98. This trade represents a 20.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the sale, the director owned 8,920 shares in the company, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 373,037 shares of company stock worth $50,731,512. Corporate insiders own 0.27% of the company’s stock.
Hedge Funds Weigh In On Gilead Sciences
A number of hedge funds have recently made changes to their positions in the stock. Palisade Asset Management LLC acquired a new position in shares of Gilead Sciences in the third quarter worth $46,000. Wealth Watch Advisors INC bought a new stake in shares of Gilead Sciences in the third quarter valued at about $60,000. Quantbot Technologies LP acquired a new stake in shares of Gilead Sciences during the 3rd quarter valued at about $72,000. Binnacle Investments Inc increased its position in shares of Gilead Sciences by 14.3% during the 2nd quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 88 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its position in Gilead Sciences by 135.3% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 713 shares of the biopharmaceutical company’s stock worth $79,000 after buying an additional 410 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.
Gilead Sciences News Roundup
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Board raised the quarterly dividend by 3.8% to $0.82, supporting income investors and signaling confidence in cash flow. Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
- Positive Sentiment: Q4 results showed solid sales and profit performance with some outlets reporting beats or roughly inline with estimates, and management highlighted growth in liver disease and HIV products plus potential new cancer/HIV approvals this year. Gilead quarterly results beat Wall Street estimates Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products
- Neutral Sentiment: Some data items (short interest reporting) are effectively noise or inconsistent and don’t indicate a rising short-squeeze risk; treat with caution. (public short‑interest entry)
- Neutral Sentiment: Pre-earnings analyst previews and buy‑thesis pieces highlighted Yeztugo and the core portfolio as reasons for optimism, which supports medium‑term upside if launches and approvals execute. Gilead Q4 preview: Core portfolio, Yeztugo launch keep analysts optimistic ahead of earnings
- Negative Sentiment: Management set FY‑2026 EPS guidance at $8.45–8.85 and revenue guidance of $29.6–$30.0B, which sits at or below consensus estimates and drove the bulk of the sell‑off as it reduces near‑term upside expectations. Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance
- Negative Sentiment: Earnings per share results were reported as essentially flat/mixed versus estimates (variously characterized as a $0.01 miss or a small beat depending on the consensus used), reinforcing the view that guidance — not current results — is the key concern. Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates
About Gilead Sciences
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Further Reading
- Five stocks we like better than Gilead Sciences
- Think You Missed Silver? You’re Wrong. Here’s Why.
- How to collect $500-$800 weekly (BlackRock’s system)
- New gold price target
- Nvidia CEO Issues Bold Tesla Call
- HCTI: Under the Radar and Building an AI Healthcare Empire
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
